EGCG - A promising therapeutic stratagem for diabetic nephropathy

Thangarajeswari Mohan¹, Kalaiselvi Periandavan^{1*}

¹Department of Medical Biochemistry, Dr.ALMPGIBMS, University of Madras, Taramani Campus, Chennai.

*Corresponding author e.mail: pkalaiselvi2011@gmail.com

From National Conference on Interdisciplinary Research and Innovations in Biosciences, NATCON -2018. Post Graduate & Research Department of Biochemistry, Mohamed Sathak College of Arts & Science, Sholinganallur, Chennai-600119, India. 24th & 25th January 2018. American J of Bio-pharm Biochem and Life Sci 2018 January, Vol. 4 (Suppl 1): **OP57**

ABSTRACT

Diabetic nephropathy is characterized by glomerularhyperfiltration, thickening of glomerular basement membrane, mesangial matrix expansion and podocytes effacement that is associated with a decline of glomerular filtration rate and substantial proteinuria. Among the several factors associated with DN, hyperglycemia facilitates podocyte effacement via apoptosis leading to albuminuria. Although, a number of potential treatment strategies exist for diabetic nephropathy, considering the ease of use and bioavailability, phytochemicals stands distinct as the preeminent option. EGCG, a green tea catechin is one such phytochemical which possess hypoglycemic and anti-apoptotic activity. The present study aims to explore the potential of EGCG to prevent apoptosis in high-fat diet and STZ induced diabetic nephropathy in rats by analysing the cellular antioxidants and the protein expression of KIM-1, OPN, NOX2,WT-1 (podocyte specific marker). Our results validate EGCG as a potential anti-apoptotic agent evidently as it improves renal function by bolstering antioxidant status and up regulating WT-1, thereby maintaining the integrity of podocytes and consequently ameliorating diabetic nephropathy. In accordance, EGCG might be regarded as a prospective therapeutic candidate in modulating diabetic nephropathy.